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Objectives. The effects of varying concentrations of theophyl-
line on exercise-induced myocardial ischemia were evaluated in
patients with stable coronary artery disease .
Background. Theophyliiue Is a competitive antagonist of ade-
uosine and may have potential as an anti-ischemle medication. It
Is not known whether these effects on myocardial ischemia are
concentration dependent .
Methods. In a double-blind, randomized, crossover manner, I I
patients received, at I-week Intervals, placebo and each of three
theophylline doses by intravenous infusion for 45 min. Graded
exercise testing was performed before randomization and imme-
diately after each infusion . Concurrent anti-ischemic medications
were withheld for 24 h before each exercise test . Serum theophyl-
line concentrations achieved were 3 .9 ± 1 .0 mg/liter (low), 8.2 ±
1.8 mg/liter (medium) and 13.2 ± 2.3 mg/liter (high).
Pharmacologic management of myocardial ischemia has tradi-
tionally focused on vasodilation of epicardial arteries or a
reduction in myocardial oxygen demand, or both . Recently, an
alternative approach to the treatment of ischemia was pro-
posed wherein benefit may be derived from an improvement in
the maldistribution of coronary blood flow caused by endoge-
nous adenosine (1). The adenosine antagonist theophylline has
been shown to delay the onset of ischemia and to increase the
threshold for its occurrence (2-6) .
To date, most studies of the short-term effects of intra-
venous theophylline have used one dose, based on body
weight and without measured blood concentrations (2-5) .
Blood levels reported in a single study by Heller et al . (6) were
approximately 8 mg/liter, lower than the 10- to 20-mgfliter
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Results.
Compared with placebo, none of the three theophyl-
line infusions produced a significant
alteration in rest heart rate,
blood pressure, mean frequency or severity of ventricular ectopic
activity or noneardlac symptoms . The time to onset of ischemia
was progressively Increased,
with medium and high concentra-
tions achieving statistical significance. Similar patterns were ob-
served for oxygen uptake and the heart rate-systolic blood pres-
sure product at the onset of ischemia . Total exercise duration was
significantly prolonged with the medium and high concentrations .
Conclusions . It is concluded that administration of varying
doses of theophylline before exercise produces a clinically signifi-
cant and concentration-dependent improvement in the indicators
of myocardial ischemia in patients with chronic stable coronary
artery disease.
(J Am Coll Cordial 1993;22
:1155-8)
concentration range typically associated with theophylline use
in reactive airways disease (7) . Although these studies have
shown that an anti-ischemic benefit with theophylline may
exist, no systematic concentration-response comparisons have
been made of the agent . Such an approach may be useful in
determining an optimal dosing regimen to maximize therapeu-
tic effects while minimizing adverse reactions. The purpose of
the present study was to determine the effects of three serum
concentrations of theophylline on exercise-induced myocardial
ischemia and to evaluate the potential of this agent for cardiac
and noncardiac adverse effects .
Methods
Patient selection. Clinically stable patients with ischemic
coronary artery disease were evaluated for inclusion in the
study on the basis of results of exercise testing with radio-
nuclide imaging administered at the Memorial Hospital of
Rhode Island. Male and female patients were eligible for
study entry if they completed at least stage I of a Bruce
protocol and the exercise test resulted in horizontal
ST
segment depression >0.I mV, with accompanying ischemia
by radionuclide myocardial scintigraphy .
Exclusionary criteria included the following: 1) concurrent
methylxanthine, dipyridamole or digoxin therapy
; 2) known
0735-1097193/56.00
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allergy to theophylline, required use of bronchodilator therapy
or history of pulmonary disease ; 3) clinical instability
; 4) left
ventricular hypertrophy, left bundle branch block or other
baseline ST segment abnormalities preventing interpretation of
the exercise electrocardiogram (EGG)
; or 5) recent myocardial
it
tion (within 30 days), coronary artery bypass surgery
(within 3 months) or percutaneous transluminal coronary an-
gioplasty (within 3 months).
The study was approved by the Committee for the Use of
Human Subjects in Research at the Memorial Hospital of
Rhode Island. All subjects gave written informed consent
before study participation .
erkental design and medication protocol . The study
was a double-blind, placebo-controlled crossover trial using
a randomized block factorial design. After medical screening
and baseline testing, patients received, in random order, a
saline placebo and each of three theophylline doses at
weekly intervals
. The theophylline doses were administered
as a bolus infusion for 45 min using the ethylenediamine salt
aminophylline, and were estimated to achieve mean concen-
trations of 3.5, 7,5 and 12 .5 mg/liter (8) . During each infu-
sion, patients were placed in the supine position, and fre-
quent evaluations of blood pressure, symptoms and 12-lead
ECGs were made. Three ECU leads were monitored contin-
uously throughout the infusion period .
Procedures and analysis, Exercise testing. Five symptom-
limited Bruce protocol exercise tests were performed in the
fasting state at the same time of day by each patient at weekly
intervals : at baseline and immediately after each of the four
study medication infusions . All and-ischemic medications
(with the exception of sublingual nitroglycerin) were discontin-
ued 24 h before exercise testing and reinstated immediately
after each test. Three ECU leads were monitored continuously
throughout the tests, and all spontaneous ectopic activity was
recorded. Twelve-lead ECOs were recorded at the end of each
minute of exercise, at the onset of ST segment depression and
angina (if present) and until resolution of ECU changes during
recovery, Blood pressure measurements were obtained during
each stage of exercise and during recovery until return to
baseline. Standard exercise test terminate n criteria, as de-
scribed by Ellestadt (9) were used .
Oxygen uptake methods . Oxygen uptake was measured
during each exercise test by open-circuit indirect calorimetry
with an Ametek S .3A oxygen analyzer, a Beckman LB-2
carbon dioxide analyzer and a Hewlett-Packard heated dig-
ital pneumotach (model 77303A). Measurements were made
using a Douglas bag method, with collection of 30-s mixed
expired air samples during the last 30 s of each minute of
exercise (10). Calibrations were performed before each
exercise test (11).
Data aaIY* and interpretation, The ECGs were ana-
lyzed by consensus by two experienced cardiologists with-
out knowledge of patient identity or treatment . The tests
were analyzed in random order. For each subject, the lead
showing the greatest ST segment depression was determined
with the first test read and was utilized on all subsequent
.IACC Val. 22, No . 4
October 1993:1135-8
tests. Data extracted from the ECGs included the time of
onset of 0.1-mV horizontal ST segment depression, the
magnitude of ST segment depression at peak exercise, total
exercise duration and the time to onset of angina pectoris .
Theophylline assays. Whole-blood samples were col-
lected at the end of exercise, in a tube without additive and
spun at 1,200 x g for 15 min . The supernatant was extracted
and immediately frozen. Duplicate serum samples (10 p1)
were assayed for theophylline using the theophylline two-
part rate test with a Kodak Ektachem clinical analyzer
(model 400, publication MP2-46). The coefficient of variation
for this assay ranges from 2.5% to 4.9%, whereas accuracy
has been reported to correlate highly with high performance
liquid chromatographic methodology (r = 0 .99) .
Statistical analyses. Statistical analyses of the exercise
data were performed using a repeated-measures analysis of
variance with the Systat statistical package (Systat, Inc .,
Evanston, IL) (12). The Tukey Honestly Significant Differ-
ence (HSD) test was used for post hoc testing whenever
there were significant main effects (13) . The statistical sig-
nificance level was set at p < 0 .05. Data are reported as
mean value ± SD.
Results
Study patients . The study group consisted of II men,
with a mean age of 65 *_ 8 years . All patients were receiving
at least one anti-ischemic medication. Medications included
long-acting nitrates (five patients), beta-adrenergic antago-
nists (four patients) and calcium channel blocking agents
(five patients). In addition to positive responses on exercise
scintigraphy, all patients had further evidence of coronary
artery disease documented by a history of angina pectoris
(10 patients), previous myocardial infarction (4 patients),
and previous cardiac catheterization (7 patients) .
Comparison of theophylline concentrations with placebo .
Pretreatment with intravenous theophylline was completed
in all patients without complications. The mean serum
theophylline concentrations achieved were 3 .9 ± 1 .0 mg/liter
(termed "low"), 8.2 ± 1.8 mg/liter (termed "medium") and
13.2 ± 2.3 mg/liter (termed "high") . Each theophylline
concentration was significantly different from the other two
(p < 0.05) . Cardiac and noncardiac effects during the infu-
sions are shown in Table 1 . When compared with placebo,
none of the three theophylline concentrations produced a
significant alteration in heart rate or systolic or diastolic
blood pressure . In addition, there was no change in the mean
rate or severity of ventricular premature complexes or
noncardiac symptoms, such as transient light-headedness or
headaches. Finally, the frequency and severity of ventricular
ectopic activity observed during exercise after placebo and
theophylline infusions were similar.
Effects of theophylline on ischemia . The effects of varying
concentrations of theophylline on the onset of exercise-
induced ischemia were evaluated (Table 2) . All patients
demonstrated ECU evidence of ischemia during each exer-
JACC Vol, 22, No . 4
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Table 1 . Effect of Varying Doses of Intravenous Theophyllitle Before Exercise
vise test . After each theophylline infusion, the time to onset
of ECO changes was progressively delayed, with the me-
dium and high concentrations achieving statistical signifi-
cance (Fig . 1). A similar pattern was shown with the uptake
of oxygen at the onset of ischemia. The heart rate-systolic
blood pressure product at the onset of ischemia also in-
creased in a stepwise fashion, and all three concentrations of
theophylline were significantly different from placebo (Table
2). Only five patients experienced angina during the baseline
exercise protocol . In this subset of patients, no differentia-
tion could be made among study treatments with regard to
the onset of angina pectoris . The effects of varying concen-
trations of theophylline on peak exercise conditions were
also evaluated, with results analogous to those at the onset
of ischemia (Table 3) .
Discussion
It has been proposed that in coronary artery disease,
'wreased myocardial oxygen demand results in vasodilation
and altered distribution of transmural myocardial blood flow
from endocardium to epicardium (1,14). Endogenous ade-
nosine may play an important role in the mediation of this
vasodilation . Theophylline has been shown in vitro to be a
moderately potent adenosine antagonist (15) . Although
previous studies have associated short-term theophylline
Table 2. Effect of Varying Doses of Intravenous Theophylline on
the Onset of Myocardial Ischemia in 11 Study Patients
*p < 0.05 compared with baseline and p lacebo. tp < 0 .05 compared with
placebo. Values presented are mean value ± SD or p value
. ANOVA
analysis of variance; HR x SBP = heart rate-systolic blood pressure product
(x 103).
Thenphylline Concentration
WI
.a130UR ET AL
.
1157
Placebo
Low
Medium
High
Before
After Before
After Before
After Before
After
	_
There was no statistically significant difference in any of the variables between placebo and the low, medium or high concentration of theophylline
. Values
presented are mean value ± SD or number
. ADR = adverse drug reaction (positional light-headedness,
headache). After = after theophylline infusion
;
Before = before infusion; VPBs = ventricular premature beats
.
administration with reduced myocardial ischemia, the
outcomes have not been evaluated for concentration depen-
dency (2-6). The present study demonstrates that in patients
with coronary artery disease, the factors related to myocar-
dial ischemia are altered in a concentration-dependent man-
ner by theophylline .
Rationale for theophylline concentrations. The concentra-
tion range used in the present study was chosen to represent
a wide variation for determining potential drug effect . The
midrange concentration of 8 mg/liter was previously shown
to improve exercise tolerance, but it was unknown whether
a concentration within the traditional "therapeutic range" of
theophylline (10 to 20 mg/liter) would produce added benefit
(6). The lowest concentration tested, approximately 4 mg/
liter, was chosen to parallel the dose of theophylline
used to reverse the clinical and ECG effects of dipyridamole
given during pharmacologic stress testing (16-18) . Typically,
the dosage ranges from 75 to 150 mg of am nophylline and
would be expected to result in serum concentrations of
<5 mg/liter .
In the present study, theophylline at the lowest concen-
tration produced a statistically significant 30-s increase in the
time to ischemia and exercise duration, a result that may
reflect the small number of subjects tested . However, the
Figure 1 . Effects of increasing theophylline concentrations on the
time to onset of significant ST segment depression . Data are
presented as mean value ± SD. `p < 0.05 compared with baseline
and placebo .
10
THEOPHYLL NE CONCENTRATION
Heart rate (beats/min) 65 ± 11 64
± 10 65 ± 12 64 _ 10
62 ± 7
61 ± 7 68 ± 10
70
±
14
Systolic blood pressure (mm Hg)
141 ± 20 147 ± 22 142
± 23 149 ± 22 147
± 16 149 ± 17 145 ± 16
146 ± 22
Diastolic blood pressure (mm Hg) 84 ± 9
83 ± 11 83 ± 5
83 ± 5 83 ± 7 83 ± 9
83 ± 9
85 ± 10
VPBs/h 4.7±8.2
11 .5 ± 29 .2 7 .0 ± 13 .0
4.1±7 .v
Total AADBR 1 2 5 3
Time
(min)
Oxygen Uptake
(mg/kg per min) HR x SBP
Baseline 4 .5 ± 2 .1 15 .2 ± 2 .7 19 .7 ± 3.2
Placebo 4.5 t 2 .0 14 .0 :t 3 .1 18 .6 ± 2.6
Low 5.0 ± 1 .8 15 .3 ± 3 .0 21.1±3
.5*
Medium
5
.8 ± 2 .6* 16
.4 ± 4 .It 21 .6 ± 3.6*
High 6.2 ± 2 .5* 17 .0 ± 3 .8* 22
.8 ± 4.9*
p value (ANOVA)
< 0.0001
< 0
.0001 < 0.0001
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Table 3
. Effect of Varying Doses of Intravenous
Theophylline at
Peak Exercise in I I Study Patients
Max ST
Oxygen Uptake
Depression
Time (min) (mglkg per
min) HR
x
SBP
(mV)
Baseline 6.9 :t 2 .6
17.4 :t 3.0 22
.8 13.4 0.20 t 0.08
Placebo
7
.3
t 2 .5 17.4 14.0
22 .0 :t 3.3 0.24 :t 0.08
Low
7.8* 2 .4* 18.8
*-
4 .1 24.414.3 0.24
±
0
.09
Medium 8.012
.4t 18.914 .1 25 .1
:t 4.1t 0.21 10.09
High 8.3
t 2 .2t 19.413
.5t 25 .8 ± 4,3t 0.19
*- 0 .07#
p value < 0.0001
< 0.003 < 0 .0001
< 0 .03
(ANOVA)
*p < 0,05 compared with baseline . t
p < 0.05 compared with baseline and
placebo
. $p < 0,03 compared with placebo and low concentration . Values
presented as mean value 1 SD or p value. Max
-
maximal ; other abbrevi-
auos as In Table 2.
heart rate-systolic blood pressure product it the onset of
ischemia was increased with theophylline, a finding that
suggests that the drug can increase the threshold for myo-
cardial ischemia, even at low concentrations . Although not
part of this study, isolated improvement of the ischemic
threshold may correspond to a therapeutic benefit in patients
with ambulatory ischemia (19,20) . Increasing serum concen-
trations of theophylline were mirrored by further improve-
ments in exercise tolerance . The highest concentration ap-
peared to add a slight additional anti-ischemic benefit over
the moderate level and was without significant adverse
effect,
Competitive antagonism. With in vitro models, the antag-
onism of adenosine by theophylline appears to be competi-
tive (21), a result that may explain the concentration-
response gradient of theophylline found in the present study .
It is unknown whether still higher concentrations would
produce a greater effect on the outcomes of exercise . How.
ever, caution would be warranted in light of potential the .
ophylline toxicity at higher blood levels (22). The onset of
angina pectoris was not affected by theophylline In the
present study. However, the presence of angina with exer-
cise was not a study entry criterion and occurred in only 40%
of patients, an inadequate number for evaluation . In previ-
ous studies (2-6) with a greater number of patients demon-
strating angina, theophylline was shown to delay the onset of
exercise-induced angina .
Cmidmia. Administration of varying concentrations of
theophylline before exercise testing resulted in a concentra-
tion.dependent decrease in myocardial ischemia. The magni-
tude of a nti-iachemic benefit created by intravenous theophyl .
line in this study was substantial, producing an 11% to 38%
increase in the taste to onset of myocardial ischemia over the
conceftilka range tested. This improvementcompares favor-
ably with maximized therapeutic regimens with traditional
anti is motions (23). These beneficial effects were
not associated with serious side effects ; thus, theophylliim is a
promising addition and alternative to traditional agents for the
management of myocardial ischemia.
JACC Vol . 22, No. 4
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